4
Changes in Ownership
Roivant Sciences Ltd. Filed Acc 0001140361-25-045906
CEO sold 1,740,000 shares at $21.68 ($37,723,200)
- CEO acquired 3,870,659 shares (option exercise)
- CEO disposed of 2,130,659 shares (other)
From the SEC's structured data for this filing
Trades in this filing
| Insider | Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| Gline Matthew CEO | 2025-12-15 | Option exercise | +234,096 | $4.06 | $950,430 | 17,521,177 | D |
| Gline Matthew CEO | 2025-12-15 | Sale | −230,357 | $21.68 | $4,994,140 | 17,290,820 | D |
| Gline Matthew CEO | 2025-12-15 | Other disposition | −3,739 | $21.68 | $81,062 | 17,287,081 | D |
| Gline Matthew CEO | 2025-12-15 | Option exercise | +1,363,711 | $12.68 | $17,291,855 | 18,650,792 | D |
| Gline Matthew CEO | 2025-12-15 | Sale | −566,116 | $21.68 | $12,273,395 | 18,084,676 | D |
| Gline Matthew CEO | 2025-12-15 | Other disposition | −797,595 | $21.68 | $17,291,860 | 17,287,081 | D |
| Gline Matthew CEO | 2025-12-15 | Option exercise | +2,272,852 | $12.68 | $28,819,763 | 19,559,933 | D |
| Gline Matthew CEO | 2025-12-15 | Sale | −943,527 | $21.68 | $20,455,665 | 18,616,406 | D |
| Gline Matthew CEO | 2025-12-15 | Other disposition | −1,329,325 | $21.68 | $28,819,766 | 17,287,081 | D |
| Derivatives | |||||||
| Gline Matthew CEO | 2025-12-15 | Option exercise · Stock Option (Right to Buy) | −234,096 | 0 | D | ||
| Gline Matthew CEO | 2025-12-15 | Option exercise · Stock Option (Right to Buy) | −1,363,711 | 0 | D | ||
| Gline Matthew CEO | 2025-12-15 | Option exercise · Stock Option (Right to Buy) | −2,272,852 | 0 | D | ||
| Open-market sales · 1,740,000 sh · avg $21.68 · $37,723,200 | |||||||
Loading xslF345X05/form4.xml…